
[CLAIMS]

[Claim 1] A compound represented by the general formula (I):




(I)

wherein R^1 represents (1) a halogen atom, (2) a cyano group, (3) a C1-4 alkyl, (4) a C1-4 alkoxy or (5) a C3-8 cycloalkyl, wherein the C1-4 alkyl, the C1-4 alkoxy and the C3-8 cycloalkyl may be respectively and independently substituted with 1 to 3 halogen atoms and/or cyano groups; p represents an integer of 0 to 2; when p is 2, a plurality of R^1 may be the same or different; R^2 and R^3 respectively and independently represent a hydrogen atom or a C1-4 alkyl; R^4 represents a hydrogen atom; or R^2 and R^4 together with an atom to which the R^2 and R^4 are attached may form a 5- to 8-membered nitrogen-containing saturated heterocycle; L represents (1) a bond, (2) $-CR^A=CR^B\rightarrow$ or (3) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); R^A, R^B and R^D respectively and independently represent a hydrogen atom or a C1-4 alkyl; X^1 and X^2 respectively and independently represent a halogen atom;

a salt thereof, an N-oxide thereof.


[Claim 2] The compound according to claim 1, represented by the general formula (I-1):



(I-1)

wherein L^1 represents (1) $-CR^A=CR^B\rightarrow$ or (2) $-C(=O)-NR^D\rightarrow$ (wherein in each group, the arrow indicates the site of binding to the pyridine ring); and other symbols have the same meanings as described in claim 1,
a salt thereof, an N-oxide thereof.

[Claim 3] The compound according to claim 1, represented by the general formula (I-4):



(I-4)

wherein R^{24} represents a hydrogen atom or a C1-4 alkyl; and other symbols have the same meanings as described in claim 1, a salt thereof, an N-oxide thereof.

[Claim 4] The compound according to claim 1, which is selected from the group consisting of the following compounds:

(1)

N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)

1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)

3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)

(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)

3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-

1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile;

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide;

(11)

1-(4-{5-(3,5-dichlorophenyl)-4-[(4aS,8aS)-octahydro-6H-pyrido[3,4-b][1,4]oxazin-6-yl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(12)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(13)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(14)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(15)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(16)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(17)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(18)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(19)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(20)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(21)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof.

[Claim 5] The compound according to claim 2, which is selected from the group consisting of the following compounds:

(1)

N-[4-(4-amino-1-piperidinyl)-5-(3-chloro-5-fluorophenyl)-3-pyridinyl]-3-chlorobenzamide;

(2)

1-{3-(3-chloro-5-fluorophenyl)-5-[(E)-2-(3-chlorophenyl)vinyl]-4-pyridinyl}-4-piperidineamine;

(3)

3-{(E)-2-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]vinyl}benzonitrile;

(4)

(4aS,8aS)-6-{3-(3,5-dichlorophenyl)-5-[(E)-2-(3-fluorophenyl)vinyl]-4-pyridinyl}octahydro-1H-pyrido[3,4-b][1,4]oxazine;

(5)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-4-piperidineamine;

(6)

3-[(E)-2-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}vinyl]benzonitrile;

(7)

1-{3-(3,5-dichlorophenyl)-5-[(1E)-2-(3-fluorophenyl)-1-propen-1-yl]-4-pyridinyl}-N-ethyl-4-piperidineamine;

(8)

3-{(1E)-1-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-1-propen-2-yl}benzonitrile;

(9)

3-[(1E)-1-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}-1-propen-2-yl]benzonitrile; and

(10)

N-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]-5-fluoro-2-methoxybenzamide,

a salt thereof, an N-oxide thereof.

[Claim 6] The compound according to claim 3, which is selected from the group consisting of the following compounds:

(1)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(2)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-4-piperidineamine;

(3)

1-{3-(3-chloro-5-fluorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(4)

1-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}cyclopropanecarbonitrile;

(5)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-4-piperidineamine;

(6)

1-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)cyclopropanecarbonitrile;

(7)

2-{4-[4-(4-amino-1-piperidinyl)-5-(3,5-dichlorophenyl)-3-pyridinyl]phenyl}-2-methylpropanenitrile;

(8)

2-(4-{5-(3,5-dichlorophenyl)-4-[4-(ethylamino)-1-piperidinyl]-3-pyridinyl}phenyl)-2-methylpropanenitrile;

(9)

1-{3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine; and

(10)

1-{3-(3,5-dichlorophenyl)-5-[4-(difluoromethoxy)phenyl]-4-pyridinyl}-N-ethyl-4-piperidineamine,

a salt thereof, an N-oxide thereof.

[Claim 7] A pharmaceutical composition comprising the compound according to claim 1, a salt thereof, an N-oxide thereof and a pharmaceutically acceptable carrier.

[Claim 8] The pharmaceutical composition according to claim 7, which is a prophylactic and/or therapeutic agent for a somatostatin-related disease.

[Claim 9] The pharmaceutical composition according to claim 8, wherein the somatostatin-related disease is acromegaly or a gastrointestinal symptom accompanying gastrointestinal obstruction.

[Claim 10] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof in combination with at least one drug selected from the group consisting of pegvisomant, bromocriptine and cabergoline.

[Claim 11] A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof in combination with at least one drug selected from the group consisting of prochlorperazine, levomepromazine, risperidone, metoclopramide, domperidone, diphenhydramine, chlorpheniramine, dimenhydrinate, promethazine, diprophylline, famotidine, cimetidine, scopolamine, tropisetron, granisetron, ondansetron, azasetron, ramosetron, indisetron, palonosetron, cisapride, mosapride, dexamethasone, betamethasone, prednisolone, olanzapine, quetiapine, perospirone, methylnaltrexone and morphine.